問卷

TPIDB > Search Result

Search Result

篩選

List

1449Cases

2024-08-30 - 2028-03-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2022-04-05 - 2024-07-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-09-01 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-12-01 - 2028-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-04-30 - 2026-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-12-01 - 2026-12-31

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-10-01 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2022-05-01 - 2025-05-09

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2023-02-01 - 2025-12-31

Phase III

Completed
An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG)
  • Condition/Disease

    Severe Hypertriglyceridemia

  • Test Drug

    Olezarsen (ISIS 678354)

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites